BPTF

Across TCGA pan-cancer cohorts, BPTF mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BPTF data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BPTF mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BPTF expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

HNSC, PDAC, and GBM are the cancer types where BPTF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.690	0.929	.003	46	view →
PDAC	OS	Tertile	IV	0.973	0.414	.024	9	view →
GBM	OS	Quartile	All	0.656	0.476	.027	6	view →
LSCC	OS	Median	All	0.894	0.748	.027	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BPTF–HNSC (DFS)

Open the HNSC breakdown →